Online citations, reference lists, and bibliographies.

Saccharomyces Cerevisiae-Based Probiotics As Novel Antimicrobial Agents To Prevent And Treat Vaginal Infections

R. Gaziano, Samuele Sabbatini, E. Roselletti, S. Perito, Claudia Monari
Published 2020 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Vaginal infections affect 70% of women during their lifetimes and account for millions of annual doctors’ visits. These infections are predominantly represented by vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV). Although standard antimicrobial agents remain the major strategy for the prevention and treatment of vaginal infections, both VVC and BV are difficult to treat due to high rates of resistance and recurrence, high probability of complications, and negative effects on the vaginal microbiota. This review focuses on a new approach of yeast-based probiotics for the prevention and/or treatment of these common vaginal infections.
This paper references
Gardnerella vaginalis bacteremia: a review
L. G. Reimer (1984)
10.4103/0253-7613.93859
A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis
J. Thulkar (2012)
10.29063/AJRH2017/V21I2.12
The Threat of Aerobic Vaginitis to Pregnancy and Neonatal Morbidity.
Eveline Kaambo (2017)
10.1007/s00384-019-03462-4
Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome
Ravichandran Gayathri (2019)
10.1371/journal.pone.0079812
Diverse Vaginal Microbiomes in Reproductive-Age Women with Vulvovaginal Candidiasis
Mu-biao Liu (2013)
10.1111/lam.13105
The action mechanism and biocontrol potentiality of novel isolates of Saccharomyces cerevisiae against the aflatoxigenic Aspergillus flavus.
M Marwa Abdel-Kareem (2019)
A randomized clinical trial of Saccharomyces cerevisiae
(2015)
Bacterial vaginosis and desquamative
J. 1128CMR.00075-15 Paavonen (2018)
10.3389/fmicb.2016.00879
Autophagy and Reactive Oxygen Species Are Involved in Neutrophil Extracellular Traps Release Induced by C. albicans Morphotypes
S. Kenno (2016)
10.1093/infdis/jiz365
Vaginal Epithelial Cells discriminate between yeast and hyphae of C. albicans in women who are colonized with or have vaginal candidiasis.
Elena Roselletti (2019)
10.1086/511430
Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines.
K. Workowski (2007)
10.1128/CMR.00075-15
The Human Microbiome during Bacterial Vaginosis
A. Onderdonk (2016)
10.1128/AEM.02130-10
Effect of a New Probiotic Saccharomyces cerevisiae Strain on Survival of Escherichia coli O157:H7 in a Dynamic Gastrointestinal Model
Lucie Etienne-Mesmin (2010)
[Treatment of oral candidiasis].
Jolán Bánóczy (2003)
10.1016/j.ajog.2011.02.060
Severity of bacterial vaginosis and the risk of sexually transmitted infection.
J. Allsworth (2011)
Effect of Saccharomyces cerevisiae strain UFMG A-905
A T (2015)
10.1097/MIB.0000000000000280
Saccharomyces cerevisiae CNCM I-3856 Prevents Colitis Induced by AIEC Bacteria in the Transgenic Mouse Model Mimicking Crohn's Disease
A. Sivignon (2015)
10.1097/OLQ.0b013e3181ca3cac
Prevalence and Risks for Bacterial Vaginosis in Women Who Have Sex With Women
J. Marrazzo (2010)
Saccharomyces cerevisiae CNCM I-3856 as a Natural Breakthrough for Vaginal Health: a clinical study
A. Cayzeele-Decherf (2017)
10.1016/j.diagmicrobio.2015.10.006
Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis.
J. Schuyler (2016)
10.1016/j.jsps.2013.07.001
Role of Probiotics in health improvement, infection control and disease treatment and management
A.A. Amara (2015)
10.1097/AOG.0000000000000551
Management of persistent vaginitis.
Paul Nyirjesy (2014)
10.1086/503780
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
C. Bradshaw (2006)
10.3748/wjg.v25.i18.2188
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections
D. Czerucka (2019)
10.1038/s41598-017-17649-8
NLRP3 inflammasome is a key player in human vulvovaginal disease caused by Candida albicans
E. Roselletti (2017)
10.1186/1472-6831-10-18
Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli - an in vitro study
P. Hasslöf (2010)
10.1111/j.1365-2672.2011.04977.x
The aetiology of bacterial vaginosis.
Y. Turovskiy (2011)
10.1128/mBio.02307-19
Probiotic Yeasts Inhibit Virulence of Non-albicans Candida Species
Lohith Kunyeit (2019)
10.23736/S0392-0488.17.05683-8
Management of mycoses in daily practice.
L. Drago (2017)
In vitro evaluation
J. A. Cuaron-Ibarguengoytia (2005)
Animal Feeding Stuffs
(2009)
10.1128/mBio.00724-15
Secretory Aspartyl Proteinases Cause Vaginitis and Can Mediate Vaginitis Caused by Candida albicans in Mice
Eva Pericolini (2015)
10.1080/21505594.2016.1184385
In vivo induction of neutrophil chemotaxis by secretory aspartyl proteinases of Candida albicans
E. Gabrielli (2016)
10.1080/21505594.2018.1464362
Saccharomyces cerevisiae–based probiotic as novel anti-microbial agent for therapy of bacterial vaginosis
Samuele Sabbatini (2018)
10.3168/JDS.S0022-0302(04)73546-8
Screening of dairy yeast strains for probiotic applications.
H. Kumura (2004)
10.1080/21505594.2016.1237332
The vaginal mycobiome: A contemporary perspective on fungi in women's health and diseases
L. Bradford (2017)
10.1099/JMM.0.46525-0
Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice.
F. Martins (2007)
10.1051/DST/2010001
Screening for the potential probiotic yeast strains from raw milk to assimilate cholesterol
L. Chen (2010)
Treatment of oral candidiasis (thrush) by Saccharomyces cerevisiae
Mariappan Premanathan (2011)
The human vaginal bacterial biota
S. 2050640615602571 Srinivasan (2008)
Vaginal heparan sulfate
Recomm. Rep (2017)
10.3748/wjg.v23.i2.336
Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis
Amélie Cayzeele-Decherf (2017)
10.1128/MMBR.67.3.400-428.2003
Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis
J. Naglik (2003)
10.1097/01.AOG.0000275282.60506.3d
Effectiveness of Two Tinidazole Regimens in Treatment of Bacterial Vaginosis: A Randomized Controlled Trial
C. Livengood (2007)
10.1097/01.qai.0000146599.47925.e0
HIV-Inducing Factor in Cervicovaginal Secretions Is Associated With Bacterial Vaginosis in HIV-1-Infected Women
J. Cohn (2005)
10.2217/FMB.15.52
Experimental models of vaginal candidiasis and inflammation.
Anna Vecchiarelli (2015)
The aetiology
K. Sutyak Noll (2011)
10.1097/00008480-200308000-00006
Sexually transmitted diseases treatment guidelines
G. Burstein (2003)
10.1007/s00248-012-0084-0
Increased Diversity of Fungal Flora in the Vagina of Patients with Recurrent Vaginal Candidiasis and Allergic Rhinitis
Renyong Guo (2012)
In vitro evaluation of the binding capacity of Saccharomyces cerevisiae Sc47 to adhere to the wall of Salmonella spp.
Luis Perez-Sotelo (2005)
10.1093/infdis/jiu131
Gardnerella vaginalis outcompetes 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in vitro biofilm formation model.
P. Alves (2014)
10.1128/mBio.00211-17
Vaginal Heparan Sulfate Linked to Neutrophil Dysfunction in the Acute Inflammatory Response Associated with Experimental Vulvovaginal Candidiasis
J. Yano (2017)
10.3920/BM2015.0018
Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease.
Fabiana C. P. Tiago (2015)
10.1126/scitranslmed.3003605
Temporal Dynamics of the Human Vaginal Microbiota
P. Gajer (2012)
Extra-vaginal infection
Y. L. Boustouller (1987)
Yeasts as probiotics: Mechanisms
T. J. Mansell (2020)
10.1073/pnas.1002611107
Vaginal microbiome of reproductive-age women
J. Ravel (2010)
Identification of intrinsically metronidazole-resistant
D. W. Hilbert (2016)
10.1016/J.AJOG.2007.06.039
An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole.
A. Swidsinski (2008)
Hemophilus vaginalis bacteremia.
C. Adeniyi-Jones (1980)
10.1371/journal.pone.0054379
Characterization of the Vaginal Micro- and Mycobiome in Asymptomatic Reproductive-Age Estonian Women
Tiina Drell (2013)
10.1186/s12905-015-0197-y
Common causes of vaginal infections and antibiotic susceptibility of aerobic bacterial isolates in women of reproductive age attending at Felegehiwot referral Hospital, Ethiopia: a cross sectional study
Wondemagegn Mulu (2015)
A Randomized Double-blind Placebo-controlled Trial
J. Smith (2004)
10.1007/978-3-642-83312-0
Vulvovaginal Candidosis
Dr. Werner Mendling (1988)
10.1099/jmm.0.042283-0
Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics.
F. C. P. Tiago (2012)
10.1080/21505594.2016.1213937
Therapeutic activity of a Saccharomyces cerevisiae-based probiotic and inactivated whole yeast on vaginal candidiasis
Eva Pericolini (2017)
10.1097/QAD.0b013e3283536ba8
Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders
A. Cassone (2012)
10.1007/s00253-018-9053-y
Anti-infectious properties of the probiotic Saccharomyces cerevisiae CNCM I-3856 on enterotoxigenic E. coli (ETEC) strain H10407
C. Roussel (2018)
Chronic vulvovaginal candidiasis.
Daniel R Retzer (2004)
10.1155/2008/750479
The Human Vaginal Bacterial Biota and Bacterial Vaginosis
S. Srinivasan (2008)
10.1128/JB.00056-12
Comparative genomic analyses of 17 clinical isolates of Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent with subspeciation into genovars.
A. Ahmed (2012)
10.1016/j.resmic.2017.02.005
Candida and its dual lifestyle as a commensal and a pathogen.
M. Cauchie (2017)
10.1016/j.annepidem.2017.08.010
Recurrent vulvovaginal candidiasis.
Freida A Blostein (2017)
10.3109/1040841X.2015.1091805
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors
B. Gonçalves (2016)
10.1177/2050640615602571
Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation
R. Spiller (2016)
10.1080/1040841X.2017.1291579
Etiology of bacterial vaginosis and polymicrobial biofilm formation
Hyunsul Jung (2017)
10.1371/journal.pone.0154086
Screening of Compounds against Gardnerella vaginalis Biofilms
Cornelia Gottschick (2016)
10.1371/journal.ppat.1003965
Candida Vaginitis: When Opportunism Knocks, the Host Responds
B. M. Peters (2014)
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Gaziano (2020)
10.1016/j.fgb.2020.103333
Yeasts as probiotics: mechanisms, outcomes, and future potential.
Swastik Sen (2020)
10.1086/322613
Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract.
S. Cu-Uvin (2001)
10.1038/nrgastro.2014.66
Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
C. Hill (2014)
10.1258/ijsa.2011.011012
European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011
J. Sherrard (2011)
10.1016/j.dld.2014.11.007
A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.
G. Pineton de Chambrun (2015)
10.3389/fmicb.2019.01469
Saccharomyces cerevisiae CNCM I-3856 as a New Therapeutic Agent Against Oropharyngeal Candidiasis
Elena Roselletti (2019)
Increased diversity
R. j.1471-0528.2006.01122.x Guo (2012)
10.1097/OLQ.0b013e318156a5d0
A Delicate Balance: Risk Factors for Acquisition of Bacterial Vaginosis Include Sexual Activity, Absence of Hydrogen Peroxide-Producing Lactobacilli, Black Race, and Positive Herpes Simplex Virus Type 2 Serology
T. Cherpes (2008)
10.1093/infdis/167.3.783
Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.
J. Sobel (1993)
Gardnerella vaginalis bacteremia: a review of thirty cases.
L. Reimer (1984)
10.1086/523331
The safety of probiotics.
D. Snydman (2008)
10.1136/pgmj.55.647.645
Candida vaginitis
R. Hurley (1979)
10.1056/NEJMra1808418
Bacterial Vaginosis and Desquamative Inflammatory Vaginitis
J. Paavonen (2018)
BMC Womens Health 15:42
sectional study (2003)
Animal Feeding Stuffs, CEN/TS 15790:2008
European Committee for Standardization (2009)
10.1111/j.1471-0528.2006.01122.x
Aetiology of preterm labour: bacterial vaginosis
S. Guaschino (2006)
10.1017/S0950268800061835
Extra-vaginal infection caused by Gardnerella vaginalis.
A. Johnson (1987)
10.3920/BM2017.0099
Saccharomyces cerevisiae-based probiotic as novel anti-fungal and anti-inflammatory agent for therapy of vaginal candidiasis.
E. Gabrielli (2018)
10.2323/JGAM.51.83
Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice.
Flariano S Martins (2005)
10.1001/JAMA.291.11.1368
Evaluation of vaginal complaints.
M. Anderson (2004)
10.1128/IAI.02895-14
Induction of Caspase-11 by Aspartyl Proteinases of Candida albicans and Implication in Promoting Inflammatory Response
E. Gabrielli (2015)



Semantic Scholar Logo Some data provided by SemanticScholar